Expression of the SARS-CoV-2 receptor-binding domain by live attenuated influenza vaccine virus as a strategy for designing a bivalent vaccine against COVID-19 and influenza
Abstract Influenza and SARS-CoV-2 are two major respiratory pathogens that cocirculate in humans and cause serious illness with the potential to exacerbate disease in the event of co-infection. To develop a bivalent vaccine, capable of protecting against both infections, we inserted the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein into hemagglutinin (HA) molecule or into the open reading frame of the truncated nonstructural protein 1 (NS1) of live attenuated influenza vaccine (LAIV) virus and assessed phenotypic characteristics of the rescued LAIV-RBD viruses, as well as their immunogenicity in mouse and Syrian hamster animal models. A panel of 9 recombinant LAIV-RBD viruses was rescued using the A/Leningrad/17 backbone. Notably, only two variants with RBD insertions into the HA molecule could express sufficient quantities of RBD protein in infected MDCK cells. Intranasal immunization of mice induced high levels of anti-influenza antibody responses in all chimeric LAIV-RBD viruses, which was comparable to the LAIV virus vector. The RBD-specific antibody responses were most pronounced in the variant expressing RBD194 fragment as a chimeric HA protein. This candidate was further tested in Syrian hamsters and was shown to be immunogenic and capable of protecting animals against both infections..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Virology journal - 21(2024), 1 vom: 09. Apr. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Stepanova, Ekaterina [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Bivalent vaccine |
|---|
| Anmerkungen: |
© The Author(s) 2024 |
|---|
| doi: |
10.1186/s12985-024-02350-w |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR055461751 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR055461751 | ||
| 003 | DE-627 | ||
| 005 | 20240409064754.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240409s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12985-024-02350-w |2 doi | |
| 035 | |a (DE-627)SPR055461751 | ||
| 035 | |a (SPR)s12985-024-02350-w-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 100 | 1 | |a Stepanova, Ekaterina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Expression of the SARS-CoV-2 receptor-binding domain by live attenuated influenza vaccine virus as a strategy for designing a bivalent vaccine against COVID-19 and influenza |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2024 | ||
| 520 | |a Abstract Influenza and SARS-CoV-2 are two major respiratory pathogens that cocirculate in humans and cause serious illness with the potential to exacerbate disease in the event of co-infection. To develop a bivalent vaccine, capable of protecting against both infections, we inserted the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein into hemagglutinin (HA) molecule or into the open reading frame of the truncated nonstructural protein 1 (NS1) of live attenuated influenza vaccine (LAIV) virus and assessed phenotypic characteristics of the rescued LAIV-RBD viruses, as well as their immunogenicity in mouse and Syrian hamster animal models. A panel of 9 recombinant LAIV-RBD viruses was rescued using the A/Leningrad/17 backbone. Notably, only two variants with RBD insertions into the HA molecule could express sufficient quantities of RBD protein in infected MDCK cells. Intranasal immunization of mice induced high levels of anti-influenza antibody responses in all chimeric LAIV-RBD viruses, which was comparable to the LAIV virus vector. The RBD-specific antibody responses were most pronounced in the variant expressing RBD194 fragment as a chimeric HA protein. This candidate was further tested in Syrian hamsters and was shown to be immunogenic and capable of protecting animals against both infections. | ||
| 650 | 4 | |a SARS-CoV-2 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a COVID-19 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Influenza |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Bivalent vaccine |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Recombinant influenza virus |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Virus vectored vaccine |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Immunogenicity |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Syrian hamsters |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Isakova-Sivak, Irina |e verfasserin |4 aut | |
| 700 | 1 | |a Mezhenskaya, Daria |e verfasserin |4 aut | |
| 700 | 1 | |a Niskanen, Sergei |e verfasserin |4 aut | |
| 700 | 1 | |a Matyushenko, Victoria |e verfasserin |4 aut | |
| 700 | 1 | |a Bazhenova, Ekaterina |e verfasserin |4 aut | |
| 700 | 1 | |a Rak, Alexandra |e verfasserin |4 aut | |
| 700 | 1 | |a Wong, Pei Fong |e verfasserin |4 aut | |
| 700 | 1 | |a Prokopenko, Polina |e verfasserin |4 aut | |
| 700 | 1 | |a Kotomina, Tatiana |e verfasserin |4 aut | |
| 700 | 1 | |a Krutikova, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Legotskiy, Sergei |e verfasserin |4 aut | |
| 700 | 1 | |a Neterebskii, Bogdan |e verfasserin |4 aut | |
| 700 | 1 | |a Ostroukhova, Tatiana |e verfasserin |4 aut | |
| 700 | 1 | |a Sivak, Konstantin |e verfasserin |4 aut | |
| 700 | 1 | |a Orshanskaya, Yana |e verfasserin |4 aut | |
| 700 | 1 | |a Yakovlev, Kirill |e verfasserin |4 aut | |
| 700 | 1 | |a Rudenko, Larisa |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Virology journal |d BioMed Central, 2004 |g 21(2024), 1 vom: 09. Apr. |w (DE-627)SPR029231027 |w (DE-600)2160640-7 |x 1743-422X |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2024 |g number:1 |g day:09 |g month:04 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s12985-024-02350-w |m X:VERLAG |x 0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2024 |e 1 |b 09 |c 04 | ||